A Review of the FDA Approval Pathway for Biosimilars and a Real-World Example of the Use of Infliximab

Proceed to Course

Activity Description:

Biologic medications are essential for optimal care in many disease states, but these agents have complex structures that prevent the development of conventional, low-cost generic equivalents. The United States Food and Drug Administration (FDA) has created an abbreviated approval pathway for the development of biosimilar drugs, medications highly similar to their reference products, but which can be developed with lower investment of time and resources, without compromising safety and effectiveness.

To increase knowledge of biosimilar products, this video activity reviews the FDA approval pathway for biosimilars, discusses studies required to demonstrate biosimilarity, and introduces studies on the utilization of biosimilars in real-world practice. Potential solutions to overcome barriers to biosimilar adoption are also discussed.

Learning Objectives:

Intended Audience: Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare providers.

Initial Release Date: 6/15/2023

Expiration Date: 6/14/2026

Cost and Registration: There is no fee for this activity. The program is supported by the New York State Department of Health Medicaid Prescriber Education Program (MPEP).

Accreditation Information:

For physicians/providers:

Accreditation: The University at Buffalo Jacobs School of Medicine and Biomedical Sciences is accredited by the ACCME to provide continuing medical education for physicians.

Certification: The University at Buffalo Jacobs School of Medicine and Biomedical Sciences designates this Internet Enduring Activity for a maximum of 1.0 AMA PRA Category 1 Credit (TM). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For pharmacists:

The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based activity has been assigned ACPE# 0044-0000-23-030-H01-P and will award 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Credit will be uploaded to the CPE Monitor for those who complete all components of this activity.

Activity Components for Continuing Education Credit:

To obtain continuing education credit, complete the required materials. This continuing education activity contains a pre-test, educational video presentation, supplementary handout, post-test, and program evaluation. Credit will be awarded upon successful completion of the post-test activity, with a score of over 70%.

Disclosures:

The following planners, presenters and others have either indicated financial relationships with ineligible companies or that no financial relationships exist. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ACCME Standards for Integrity and Independence in Accredited Continuing Education

Software Requirements:

• Chrome
• Firefox
• Safari
• Edge
• Internet Explorer is NOT supported
• Safari 7 and below has known compatibility issues

• Smartphones have limited support. Use a desktop or laptop computer for the best experience.
• Safari
• Chrome

For questions about this activity, please contact: pep@nysdoh.suny.edu

Back to Course Listings     Proceed to Course